Evaluate the Effect and Safety of Pu Yang Wan Wu Tang and Western Medicine on Chronic Kidney Disease
NCT ID: NCT05387187
Last Updated: 2023-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
40 participants
INTERVENTIONAL
2022-05-01
2023-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Pu Yang Wan Wu Tang is proved to have the effect of protecting nerve and blood vessel, anti-inflammation, anti-coagulation, dilating peripheral vessel, promot-ing micro circulation, improving hemodynamics, and activating central nerve system. Huangqi could attenuate podocyte injury by regulating the expression and distribu-tion of nephrin and podocin. Huangqi and Danggui are associated with fewer infiltra-tion of macrophages and limitation of renal intrinsic cell activation, which may lead to earlier and persistent reduction of proteinuria.
This research will use the compound Chinese medicine, Pu Yang Wan Wu Tang. Those treatments combined Western medicine to assess the efficacy and drug safety on the CKD cases. Series of blood and urine were collected regularly during study to prove the role of Chinese medicine in the treatment of CKD, and to assess their drug safety.
The final goal of the plan is to establish the new indication of Pu Yang Wan Wu Tang and enhance the interaction and cooperation between Chinese and Western medicine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Western and Traditional Chinese Medicine Daycare for DM Nephropathy Patients
NCT05038046
the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD
NCT03681249
Buyuan-zhixiao Formula in the Treatment of Elderly Patients With Diabetes and Multiple Metabolic Disorders
NCT06358118
Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat
NCT01612260
Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina.
NCT03171597
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pu Yang Wan Wu Tang plus Pentoxifylline
Pu Yang Wan Wu Tang plus Pentoxifylline
Pu Yang Wan Wu Tang 5g TID Pentoxifylline 100mg TID
Pentoxifylline
Pentoxifylline
Pentoxifylline 100mg TID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pu Yang Wan Wu Tang plus Pentoxifylline
Pu Yang Wan Wu Tang 5g TID Pentoxifylline 100mg TID
Pentoxifylline
Pentoxifylline 100mg TID
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants CKD stage are from 2 to 4(eGFR from 89 to 15)
* Participants under regular western medicine therapy.
* Participants who agree to follow the trial protocol.
* Participants who can complete the study treatment and assessments.
Exclusion Criteria
* Participants who are participating in other clinical trials.
* Participants with hematopoietic system diseases, severe psychiatric or psychological disorder, or cancer.
* Women who are pregnant.
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taipei Medical University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Su, Po-Hsuan
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
PO-HSUAN SU, MD
Role: PRINCIPAL_INVESTIGATOR
Taipei Medical University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taipei Medical University
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N202204011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.